KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Accumulated Expenses: 2018-2025

Historic Accumulated Expenses for Adaptive Biotechnologies (ADPT) over the last 7 years, with Sep 2025 value amounting to $12.7 million.

  • Adaptive Biotechnologies' Accumulated Expenses rose 2.79% to $12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.7 million, marking a year-over-year increase of 2.79%. This contributed to the annual value of $15.8 million for FY2024, which is 15.73% up from last year.
  • Latest data reveals that Adaptive Biotechnologies reported Accumulated Expenses of $12.7 million as of Q3 2025, which was up 30.73% from $9.7 million recorded in Q2 2025.
  • Adaptive Biotechnologies' Accumulated Expenses' 5-year high stood at $17.0 million during Q3 2021, with a 5-year trough of $7.8 million in Q1 2025.
  • For the 3-year period, Adaptive Biotechnologies' Accumulated Expenses averaged around $10.8 million, with its median value being $10.6 million (2023).
  • Per our database at Business Quant, Adaptive Biotechnologies' Accumulated Expenses soared by 222.82% in 2021 and then decreased by 27.82% in 2022.
  • Quarterly analysis of 5 years shows Adaptive Biotechnologies' Accumulated Expenses stood at $15.6 million in 2021, then climbed by 1.87% to $15.9 million in 2022, then fell by 14.12% to $13.7 million in 2023, then increased by 15.73% to $15.8 million in 2024, then grew by 2.79% to $12.7 million in 2025.
  • Its Accumulated Expenses stands at $12.7 million for Q3 2025, versus $9.7 million for Q2 2025 and $7.8 million for Q1 2025.